ArticlePloS one2013
Depletion of CD4+ CD25+ regulatory T cells promotes CCL21-mediated antitumor immunity.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis.Oncotarget · 2017Pooled it
- Prognostic value of tumor-infiltrating FoxP3+ T cells in gastrointestinal cancers: a meta analysis.PloS one · 2014Pooled it
- CTLA-4-two pathways to anti-tumour immunity?Immunotherapy advances · 2025Review
- Immunomodulation of human T cells by microbubble-mediated focused ultrasound.Frontiers in immunology · 2024Article
- Prenol, but Not Vitamin C, of Fruit Binds to SARS-CoV-2 Spike S1 to Inhibit Viral Entry: Implications for COVID-19.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Refurbishment of NK cell effector functions through their receptors by depleting the activity of nTreg cells in Dalton's Lymphoma-induced tumor microenvironment: an in vitro and in vivo study.Cancer immunology, immunotherapy : CII · 2023Article
- Short-term assays for mesenchymal stromal cell immunosuppression of T-lymphocytes.Frontiers in immunology · 2023Article
- Retraction: Depletion of CD4+ CD25+ Regulatory T Cells Promotes CCL21-Mediated Antitumor Immunity.PloS one · 2023Article
- Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma.Journal of liver cancer · 2020Review
- Identification of hepatitis B virus and liver cancer bridge molecules based on functional module network.World journal of gastroenterology · 2019Article
- Deciphering the Role of Regulatory CD4 T Cells in Oral and Oropharyngeal Cancer: A Systematic Review.Frontiers in oncology · 2018Article
- Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer.Experimental and therapeutic medicine · 2017Article
- Regulatory T-cells promote hepatitis B virus infection and hepatocellular carcinoma progression.Chronic diseases and translational medicine · 2016Review
- Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors.Oncoimmunology · 2014Article
- Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway.Cancer immunology research · 2014Article
Corrections and comments
- Retraction · 2023-02-02Concerns/Issues about Authorship/Affiliation · Concerns/Issues about Animal Welfare · Concerns/Issues about Referencing/Attributions · Duplication of Data · Duplication of/in Image · Euphemisms for Duplication · False/Forged Authorship · Upgrade/Update of Prior Notice(s) · · Original article not updated with added authors/affilitions from correction: see https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0093126
- Correction · 2014-03-27Concerns/Issues about Authorship/Affiliation · Concerns/Issues about Referencing/Attributions · Error in Text · Updated to Retraction · · Correction added the following to the original author list: Long Chen, Jie Qin, Rilun Li, Binbin Liu, Zhenjue She, Cuiping Zhong, and Chunmin Liang, and the following two affiliations were added: Lab of Tumor Immunology, Department of Anatomy and Histology & Embryology, Shanghai Medical College of Fudan University, Shanghai, China, and Liver Cancer Institute of Zhongshan Hospital, Shanghai Medical College of Fudan University, Shanghai, China;
- Erratum issuedChen, Long [added]; Qin, Jie [added]; Li, Rilun [added]; Liu, Binbin [added]; She, Zhenjue [added]; Zhong, Cuiping [added]; Liang, Chunmin [added]
- Retracted
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CCL21 is known to attract dendritic cells (DCs) and T cells that may reverse tumor-mediated immune suppression. The massive infiltration of tumors by regulatory T cells (Tregs) prevents the development of a successful helper immune response. In this study, we investigated whether elimination of CD4(+) CD25(+) Tregs in the tumor microenvironment using anti-CD25 monoclonal antibodies (mAbs) was capable of enhancing CCL21-mediated antitumor immunity in a mouse hepatocellular carcinoma (HCC) model. We found that CCL21 in combination with anti-CD25 mAbs (PC61) resulted in improved antitumor efficacy and prolonged survival, not only inhibited tumor angiogenesis and cell proliferation, but also led to significant increases in the frequency of CD4(+), CD8(+) T cells and CD11c(+) DCs within the tumor, coincident with marked induction of tumor-specific CD8(+) cytotoxic T lymphocytes (CTLs) at the local tumor site. The intratumoral immune responses were accompanied by the enhanced elaboration of IL-12 and IFN-γ, but reduced release of the immunosuppressive mediators IL-10 and TGF-β1. The results indicated that depletion of Tregs in the tumor microenvironment could enhance CCL21-mediated antitumor immunity, and CCL21 combined with anti-CD25 mAbs may be a more effective immunotherapy to promote tumor rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.